国家脑肿瘤学会圆桌研讨会报告:借鉴COVID-19经验创新脑肿瘤临床试验
2020年7月24日,国家脑肿瘤学会召开研讨会,汇集FDA、临床医生、研究者、产业界、患者倡导者等多方利益相关者,总结COVID-19经验并探讨脑肿瘤临床试验创新。报告提出增加远程医疗和去中心化试验模式的使用,作为对临床试验设计与实施具有潜在长期影响的实际创新机会。
要点
- COVID-19经验提示远程医疗可用于脑肿瘤临床试验。
- 去中心化试验模式是潜在的创新方向。
- 多方利益相关者参与研讨会并形成建议。
核心结论
- 可借鉴COVID-19经验,通过增加远程医疗和去中心化试验模式来创新脑肿瘤临床试验。
研究设计与样本
- 2020年7月24日由国家脑肿瘤学会赞助的研讨会,汇集FDA、学术与社区临床医生、研究者、产业界、临床研究组织、患者及倡导者、SNO和NCI代表等多方利益相关者。
主要发现
- 研讨会总结了COVID-19经验,并提出将远程医疗和去中心化试验模式作为实际创新机会,可能对临床试验设计与实施产生长期影响。
临床怎么用
- 在脑肿瘤临床试验中可考虑增加远程医疗和去中心化试验模式的应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On July 24, 2020, a workshop sponsored by the National Brain Tumor Society was held on innovating brain tumor clinical trials based on lessons learned from the COVID-19 experience. Various stakeholders from the brain tumor community participated including the US Food and Drug Administration (FDA), academic and community clinicians, researchers, industry, clinical research organizations, patients and patient advocates, and representatives from the Society for Neuro-Oncology and the National Cancer Institute. This report summarizes the workshop and proposes ways to incorporate lessons learned from COVID-19 to brain tumor clinical trials including the increased use of telemedicine and decentralized trial models as opportunities for practical innovation with potential long-term impact on clinical trial design and implementation.
引用
- Lee EQ, Selig W, Meehan C, et al. Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience. Neuro Oncol. 2021. PMID: 33822177. doi:10.1093/neuonc/noab082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。